SkinHealth Systems Inc. (SKIN) Form 10-Q — Aug 6, 2026
SkinHealth Systems (Nasdaq: SKIN) reported Q2 2026 net sales of $72.1 million, down 7.8% year over year, and swung to a net loss of $2.7 million (EPS -$0.02) from a $19.7 million profit a year ago that was inflated by an $18.1 million debt-exchange gain. Delivery Systems sales dropped 18.4% amid what management called unfavorable macroeconomic and credit conditions. Underlying profitability improved: operating income was $3.6 million versus a $2.7 million loss, gross margin expanded to 68.4% from 62.8%, and G&A fell 15%, while six-month net sales of $137.0 million were down 7.3% and H1 operating cash flow turned negative at -$2.9 million.
Key figures
- Revenue
- 72113000
- Total Debt
- 345209000
- Revenue Yoy
- -7.8%
- Total Assets
- 486573000
- Cash Position
- 206074000
- Shares Outstanding
- 130104671
- H1 Net Sales
- 137023000
- H1 Revenue Yoy
- -7.3%
- Q2 Gross Margin
- 68.4%
- Notes2028 Coupon
- 7.95%
- Consumables Q2 Yoy
- -3.5%
- Interest Expense Q2
- 6295000
- Notes2026 Maturity
- October 1, 2026
- Notes2028 Maturity
- November 15, 2028
- Q2 Operating Income
- 3572000
- Consumables Q2 Sales
- 53859000
- Notes2028 Principal
- 250000000
- Stockholders Equity
- 55568000
- Delivery Systems Q2 Yoy
- -18.4%
- Delivery Systems Q2 Sales
- 18254000
- Q2 Gross Margin Prior Year
- 62.8%
- H1 2026 Notes Repurchased
- $21.3 million principal for $20.2 million
- Shares Outstanding Aug3 2026
- 130140763
- Company Funded Settlement Portion
- 3000000
- Insurer Funded Settlement Portion
- 15000000
- Securities Class Action Settlement
- 18000000
- Current Portion Of Convertible Notes
- 103089000
Price after filing
Close on the filing date to close N calendar days later (from $0.71). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.